Tesamorelin & CJC-1295 & Ipamorelin Blend
A triple-blend research preparation combining tesamorelin and CJC-1295 (Mod GRF 1-29) for dual GHRH pathway activation with ipamorelin for GHS-R1a synergy.
Community Rating
No ratings yet
⚠ Research & Educational Use Only. Tesamorelin & CJC-1295 & Ipamorelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Dual GHRH pathway stimulation from two complementary analogues
- GHS-R1a synergy from ipamorelin
- Broad GH axis stimulation with complementary mechanisms
- Tesamorelin & CJC-1295 & Ipamorelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Dual GHRH pathway stimulation from two complementary analogues
- GHS-R1a synergy from ipamorelin
- Broad GH axis stimulation with complementary mechanisms
- Strong IGF-1 elevation profile
What is Tesamorelin & CJC-1295 & Ipamorelin Blend?
Tap any underlined term for an instant definition.
The Tesamorelin & CJC-1295 & Ipamorelin Triple Blend is a complex research preparation designed to maximally stimulate the GH axis through multiple complementary mechanisms. By combining two different GHRH analogues (tesamorelin and Mod GRF 1-29/CJC-1295) with a GHS (ipamorelin), this blend represents a high-potency GH research protocol.
What It Is
- Tesamorelin: stabilized GHRH analogue with documented clinical visceral fat reduction
- CJC-1295 (Mod GRF 1-29): another GHRH analogue with slightly different stability profile; pairs well with GHSPs
- Ipamorelin: clean GHS-R1a agonist for complementary somatostatin suppression
- Three-component blend for maximal GHRH + GHS synergy
How It Works
- Two GHRH analogues activate GHRHR via additive signaling at the pituitary somatotroph
- Ipamorelin adds somatostatin suppression and independent GHS-R1a stimulation
- Triple mechanism produces GH pulses substantially greater than any two-component combination
- Lower individual doses of each component reduce side effect burden while maintaining synergistic efficacy
Key Research Findings
- Component data: Each peptide has documented GH-stimulating activity; combination data is primarily from clinical experience and extrapolation
- IGF-1: Expected elevation of 80-100%+ above baseline with full triple protocol
- Body composition research: Strong lean mass gains and fat loss profile based on component mechanism overlap
Dosing From the Literature
- Research blend typically formulated at reduced individual doses: tesamorelin 500-1000 mcg + Mod GRF 1-29 100-200 mcg + ipamorelin 100-200 mcg per administration
- Once daily at bedtime
Storage and Handling
- Lyophilised: 2-8 degrees C; 24 months
- Reconstituted: 2-8 degrees C; use within 21 days
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Tesamorelin & CJC-1295 & Ipamorelin Blend. See all Peptide Blends peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Subcutaneous injection. Start with half dose to assess individual response.
Explore Further
Quick Reference
More in Peptide Blends
- Sermorelin & Ipamorelin Blend
- Sermorelin & GHRP-2 Blend
- Sermorelin & GHRP-6 Blend
- Sermorelin & GHRP-6 & GHRP-2 Triple Blend
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.